In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad317 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Vinicius Calado Nogueira de Moura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, CO, USA. Hauptthemen laut MEDLINE: Nontuberculous Mycobacteria, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Treatment of slowly growing non-tuberculous mycobacteria (SGM) is challenging. In vitro antimicrobial susceptibility testing (AST) is needed to optimize a multidrug regimen but requires weeks to result. Aggregated AST patterns, or an antibiogram, of SGM would be helpful to providers.
Objectives
We aggregated and analysed human SGM isolates sent to our laboratory from across the USA between 2018 and 2022 to describe their in vitro susceptibility patterns and construct an antibiogram.
Methods
SGM isolates’ species/subspecies and mutations in rrs or rrl were identified by a line probe assay. AST was done primarily by broth microdilution and interpreted using the latest CLSI guideline. Mutational and AST results for SGM with ≥15 isolates were collated and analysed with descriptive statistics.
Results
There were 32 different species/subspecies of SGM from 10 131 isolates between January 2018 and December 2022 from across the USA, 80% of which were from organisms in Mycobacterium avium complex (MAC). Most specimens were sputum and came from Florida (2892). MAC ranged from 94% to 100% susceptible to clarithromycin, 64% to 91% to amikacin, 2% to 31% to linezolid, and 4% to 41% to moxifloxacin. Non-MAC SGM ranged from 82% to 100% susceptible to clarithromycin, 49% to 100% to amikacin, and 76% to 100% to rifabutin, but susceptibilities to other antimicrobials varied widely. WT rrs and rrl predicted >96% of phenotypic non-resistance to amikacin and clarithromycin, respectively, whereas mutant genotypes predicted >90% of phenotypic resistance.
Conclusions
Most SGM are likely to be susceptible to clarithromycin and amikacin, complementing their treatment guidance by mycobacterial experts. Molecular identification of resistant genotypes is accurate and helpful. This antibiogram for SGM will help providers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, CO, USA.
- Department of Immunology and Microbiology, University of Colorado, Aurora, CO, USA.
- Department of Medicine, University of Colorado, Aurora, CO, USA.
- Advanced Diagnostics Laboratories, National Jewish Health, Denver, CO, USA.
ORCID-Profile: Minh-Vu H Nguyen
Zitieren
APA
Calado Nogueira de Moura, V., Nguyen, M. H., Hunkins, J. J., Daley, C. L., & Khare, R. (2023). In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad317
Vancouver
Calado Nogueira de Moura V, Nguyen MH, Hunkins JJ, Daley CL, Khare R. In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad317
BibTeX
@article{CaladoNogueiradeMoura2023,
author = {Calado Nogueira de Moura, Vinicius and Nguyen, Minh-Vu H and Hunkins, Joshua J and Daley, Charles L and Khare, Reeti},
title = {In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad317}
}
EUVIMED